Literature DB >> 25479322

Prognostic implications of arrhythmias during primary percutaneous coronary interventions for ST-elevation myocardial infraction.

Ilker Durak1, Gulmira Kudaiberdieva, Bulent Gorenek.   

Abstract

The authors reviewed current knowledge on occurrence, clinical and prognostic significance, and management of sustained ventricular arrhythmias, atrial fibrillation and bradyarrhythmias in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary interventions (PCI). Cardiac arrhythmias worsen clinical course and prognosis in patients with ST-elevation myocardial infarction undergoing primary PCI. Sustained ventricular arrhythmias developing during or early after PCI and associated with mechanical restoration of coronary flow and reperfusion do not affect mortality, whereas those related to incomplete revascularization and ongoing ischemia are associated with poor prognosis. New-onset atrial fibrillation increases mortality and stroke rates in patients undergoing primary PCI. Among bradyarrhythmias, high-degree atrioventricular block is associated with short- and long-term mortality. Prompt and complete revascularization is the cornerstone of arrhythmia management. Arrhythmias related to reperfusion do not usually require specific treatment, whereas those because of ongoing ischemia, incomplete revascularization and presence of substrate require adequate management including nonpharmacological and pharmacological therapies.

Entities:  

Keywords:  ST-elevation myocardial infarction; atrial fibrillation; high-degree atrioventricular block; percutaneous coronary intervention; ventricular fibrillation; ventricular tachycardia

Mesh:

Year:  2014        PMID: 25479322     DOI: 10.1586/14779072.2015.987127

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  1 in total

1.  The myocardial protective effect of monosodium phosphate cardioplegia in cardiopulmonary bypass in infants with an atrial septal defect.

Authors:  Fang Yang; Jie Wang; Bo Zhai
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.